
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8187136/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	¹⁸ F-FDG PET Uptake Characterization Through Texture Analysis: Investigating the Complementary Nature of Heterogeneity and Functional Tumor Volume in a Multi–Cancer Site Patient Cohort. Journal of Nuclear Medicine, 2015, 56, 38-44.	5.0	374
2	Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 426-435.	6.4	337
3	2009 EANM parathyroid guidelines. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1201-1216.	6.4	272
4	Performance of FDG PET/CT in the Clinical Management of Breast Cancer. Radiology, 2013, 266, 388-405.	7.3	224
5	European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2112-2137.	6.4	208
6	¹⁸ F-FDG PET/CT for Staging and Restaging of Breast Cancer. Journal of Nuclear Medicine, 2016, 57, 17S-26S.	5.0	135
7	Prognostic Impact of 18FDG-PET-CT Findings in Clinical Stage III and IIB Breast Cancer. Journal of the National Cancer Institute, 2012, 104, 1879-1887.	6.3	133
8	18F-FDG PET/CT bone/bone marrow findings in Hodgkin's lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1095-1105.	6.4	129
9	Molecular Imaging of Gastroenteropancreatic Neuroendocrine Tumors: Current Status and Future Directions. Journal of Nuclear Medicine, 2016, 57, 1949-1956.	5.0	119
10	The EANM practice guidelines for parathyroid imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2801-2822.	6.4	116
11	¹⁸ F-FDG PET/CT in Staging Patients with Locally Advanced or Inflammatory Breast Cancer: Comparison to Conventional Staging. Journal of Nuclear Medicine, 2013, 54, 5-11.	5.0	114
12	The Yield of ¹⁸ F-FDG PET/CT in Patients with Clinical Stage IIA, IIB, or IIIA Breast Cancer: A Prospective Study. Journal of Nuclear Medicine, 2011, 52, 1526-1534.	5.0	99
13	Triple-Negative Breast Cancer: Early Assessment with ¹⁸ F-FDG PET/CT During Neoadjuvant Chemotherapy Identifies Patients Who Are Unlikely to Achieve a Pathologic Complete Response and Are at a High Risk of Early Relapse. Journal of Nuclear Medicine, 2012, 53, 249-254.	5.0	91
14	Dose Deposits from ⁹⁰ Y, ¹⁷⁷ Lu, ¹¹¹ In, and ¹⁶¹ Tb in Micrometastases of Various Sizes: Implications for Radiopharmaceutical Therapy. Journal of Nuclear Medicine, 2016, 57, 759-764.	5.0	90
15	Functioning pulmonary metastases of thyroid cancer: does radioiodine influence the prognosis?. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 974-981.	6.4	85
16	Targeting Neuropeptide Receptors for Cancer Imaging and Therapy: Perspectives with Bombesin, Neurotensin, and Neuropeptide-Y Receptors. Journal of Nuclear Medicine, 2014, 55, 1650-1657.	5.0	85
17	Good clinical practice recommendations for the use of PET/CT in oncology. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 28-50.	6.4	85
18	Metastatic Renal Cell Carcinoma: Relationship Between Initial Metastasis Hypoxia, Change After 1 Month's Sunitinib, and Therapeutic Response: An ¹⁸ F-Fluoromisonidazole PET/CT Study. Journal of Nuclear Medicine, 2011, 52, 1048-1055.	5.0	82

#	Article	IF	CITATIONS
19	The Sentinel Node Procedure in Breast Cancer: Nuclear Medicine as the Starting Point. Journal of Nuclear Medicine, 2011, 52, 405-414.	5.0	82
20	Modern Nuclear Imaging for Paragangliomas: Beyond SPECT. Journal of Nuclear Medicine, 2012, 53, 264-274.	5.0	79
21	The Role of Radionuclide Imaging in the Surgical Management of Primary Hyperparathyroidism. Journal of Nuclear Medicine, 2015, 56, 737-744.	5.0	75
22	Comparison Between 18F-FDG PET Image–Derived Indices for Early Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer. Journal of Nuclear Medicine, 2013, 54, 341-349.	5.0	74
23	Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype. Radiology, 2015, 277, 358-371.	7.3	72
24	Preoperative imaging of parathyroid glands with technetium-99m-labelled sestamibi and iodine-123 subtraction scanning in secondary hyperparathyroidism. Lancet, The, 1999, 353, 2200-2204.	13.7	65
25	18F-FDG PET/CT Imaging for an Early Assessment of Response to Sunitinib in Metastatic Renal Carcinoma: Preliminary Study. Cancer Biotherapy and Radiopharmaceuticals, 2009, 24, 137-144.	1.0	65
26	Expression of Gastrin-Releasing Peptide Receptor in Breast Cancer and Its Association with Pathologic, Biologic, and Clinical Parameters: A Study of 1,432 Primary Tumors. Journal of Nuclear Medicine, 2017, 58, 1401-1407.	5.0	64
27	Do clinical, histological or immunohistochemical primary tumour characteristics translate into different 18F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer?. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1682-1691.	6.4	63
28	Comparison between Three Promising ß-emitting Radionuclides, ⁶⁷ Cu, ⁴⁷ Sc and ¹⁶¹ Tb, with Emphasis on Doses Delivered to Minimal Residual Disease. Theranostics, 2016, 6, 1611-1618.	10.0	62
29	Comparative effectiveness of [¹⁸ F]â€fluorocholine PETâ€CT and pelvic MRI with diffusionâ€weighted imaging for staging in patients with highâ€risk prostate cancer. Prostate, 2015, 75, 323-331.	2.3	61
30	Bone metastases of differentiated thyroid cancer: impact of early 1311-based detection on outcome. Endocrine-Related Cancer, 2007, 14, 799-807.	3.1	60
31	Contribution of PET Imaging to the Diagnosis of Septic Embolism in Patients With Pacing Lead Endocarditis. JACC: Cardiovascular Imaging, 2016, 9, 283-290.	5.3	60
32	Performance of 18F-FDG PET/CT in the Characterization of Adrenal Masses in Noncancer Patients: A Prospective Study. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2465-2472.	3.6	59
33	18F-FDG PET/CT in the early prediction of pathological response in aggressive subtypes of breast cancer: review of the literature and recommendations for use in clinical trials. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 983-993.	6.4	58
34	CELLDOSE: A Monte Carlo Code to Assess Electron Dose Distribution—S Values for 1311 in Spheres of Various Sizes. Journal of Nuclear Medicine, 2008, 49, 151-157.	5.0	53
35	Parathyroid Scintigraphy. Clinical Nuclear Medicine, 2012, 37, 568-574.	1.3	53
36	Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer. European Journal of Cancer, 2014, 50, 1864-1871.	2.8	53

#	Article	IF	CITATIONS
37	Absorbed ¹⁸ F-FDG Dose to the Fetus During Early Pregnancy: FIGURE 1 Journal of Nuclear Medicine, 2010, 51, 803-805.	5.0	52
38	High performances of 18F-fluorodeoxyglucose PET-CT in cardiac implantable device infections: A study of 40 patients. Journal of Nuclear Cardiology, 2015, 22, 787-798.	2.1	50
39	[123I]-FP-CIT and [99mTc]-HMPAO single photon emission computed tomography in a new sporadic case of rapid-onset dystonia–parkinsonism. Journal of the Neurological Sciences, 2008, 273, 148-151.	0.6	49
40	The NETPET Score: Combining FDG and Somatostatin Receptor Imaging for Optimal Management of Patients with Metastatic Well-Differentiated Neuroendocrine Tumors. Theranostics, 2017, 7, 1159-1163.	10.0	49
41	Baseline Tumor ¹⁸ F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2â^ Breast Cancer. Journal of Nuclear Medicine, 2015, 56, 824-831.	5.0	48
42	Infections in patients using ventricular-assist devices: Comparison of the diagnostic performance of 18F-FDG PET/CT scan and leucocyte-labeled scintigraphy. Journal of Nuclear Cardiology, 2019, 26, 42-55.	2.1	48
43	Unilateral Surgery for Primary Hyperparathyroidism on the Basis of Technetium Tc 99m Sestamibi and Iodine 123 Subtraction Scanning. Archives of Surgery, 2000, 135, 1461.	2.2	47
44	Estrogen receptorâ€positive/human epidermal growth factor receptor 2â€negative breast tumors. Cancer, 2013, 119, 1960-1968.	4.1	47
45	Parathyroid Scintigraphy in Renal Hyperparathyroidism. Clinical Nuclear Medicine, 2013, 38, 630-635.	1.3	47
46	Evaluation of 68Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1258-1266.	6.4	47
47	STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network. Journal of Investigative Dermatology, 2018, 138, 58-67.	0.7	47
48	¹⁸ F-FDG PET/CT for the Early Evaluation of Response to Neoadjuvant Treatment in Triple-Negative Breast Cancer: Influence of the Chemotherapy Regimen. Journal of Nuclear Medicine, 2016, 57, 536-543.	5.0	40
49	Estimation of the β+ Dose to the Embryo Resulting from ¹⁸ F-FDG Administration During Early Pregnancy: FIGURE 1 Journal of Nuclear Medicine, 2008, 49, 679-682.	5.0	39
50	Radioactive iodine therapy, molecular imaging and serum biomarkers for differentiated thyroid cancer: 2017 guidelines of the French Societies of Nuclear Medicine, Endocrinology, Pathology, Biology, Endocrine Surgery and Head and Neck Surgery. Annales D'Endocrinologie, 2017, 78, 162-175.	1.4	39
51	Lymphoscintigraphy Can Select Breast Cancer Patients for Internal Mammary Chain Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2012, 83, 1081-1088.	0.8	37
52	Hepatosplenic Candidiasis Imaged With F-18 FDG PET/CT. Clinical Nuclear Medicine, 2009, 34, 439-440.	1.3	34
53	Gallium-68: Chemistry and Radiolabeled Peptides Exploring Different Oncogenic Pathways. Cancer Biotherapy and Radiopharmaceuticals, 2013, 28, 85-97.	1.0	34
54	Parathyroid scintigraphy findings in chronic kidney disease patients with recurrent hyperparathyroidism. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 623-634.	6.4	31

#	Article	IF	CITATIONS
55	Variation of Liver SUV on 18FDG-PET/CT Studies in Women With Breast Cancer. Clinical Nuclear Medicine, 2013, 38, 422-425.	1.3	30
56	New Perspectives Offered by Nuclear Medicine for the Imaging and Therapy of Multiple Myeloma. Theranostics, 2016, 6, 287-290.	10.0	29
57	Novel insights into parathyroid hormone: report of The Parathyroid Day in Chronic Kidney Disease. CKJ: Clinical Kidney Journal, 2019, 12, 269-280.	2.9	29
58	Mapping the cellular distribution of labelled molecules by SIMS microscopy. Biology of the Cell, 1992, 74, 81-88.	2.0	28
59	Hypoxia Imaging of Uterine Cervix Carcinoma With 18F-FETNIM PET/CT. Clinical Nuclear Medicine, 2012, 37, 1065-1068.	1.3	27
60	Comparison of the binding of the gastrin-releasing peptide receptor (GRP-R) antagonist 68Ga-RM2 and 18F-FDG in breast cancer samples. PLoS ONE, 2019, 14, e0210905.	2.5	27
61	Radiation doses from 161Tb and 177Lu in single tumour cells and micrometastases. EJNMMI Physics, 2020, 7, 33.	2.7	27
62	Fatal Heart Failure After a 26-Month Combination of Tyrosine Kinase Inhibitors in a Papillary Thyroid Cancer. Thyroid, 2011, 21, 451-454.	4.5	24
63	New Fetal Dose Estimates from ¹⁸ F-FDG Administered During Pregnancy: Standardization of Dose Calculations and Estimations with Voxel-Based Anthropomorphic Phantoms. Journal of Nuclear Medicine, 2016, 57, 1760-1763.	5.0	24
64	Hodgkin lymphoma: a negative interimâ€ <scp>PET</scp> cannot circumvent the need for endâ€ofâ€ŧreatmentâ€ <scp>PET</scp> evaluation. British Journal of Haematology, 2016, 175, 652-660.	2.5	23
65	Comparison of the radiolabeled PSMA-inhibitor 1111n-PSMA-617 and the radiolabeled GRP-R antagonist 1111n-RM2 in primary prostate cancer samples. EJNMMI Research, 2019, 9, 52.	2.5	23
66	18F-FDC-PET/CT in staging, restaging, and treatment response assessment of male breast cancer. European Journal of Radiology, 2014, 83, 1925-1933.	2.6	22
67	Bone Metastases of Differentiated Thyroid Cancer: The Importance of Early Diagnosis and 1311 Therapy on Prognosis. Journal of Nuclear Medicine, 2008, 49, 1902-1903.	5.0	21
68	Tomoscintigraphy Improves the Determination of the Embryologic Origin of Parathyroid Adenomas, Especially in Apparently Inferior Glands: Imaging Features and Surgical Implications. Journal of Nuclear Medicine Technology, 2007, 35, 135-139.	0.8	20
69	Calculation of electron dose to target cells in a complex environment by Monte Carlo code "CELLDOSE― European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 130-136.	6.4	20
70	The evolving role of PET/CT in breast cancer. Nuclear Medicine Communications, 2010, 31, 271-273.	1.1	19
71	IN VIVO QUANTIFICATION OF 18F-FDG UPTAKE IN HUMAN PLACENTA DURING EARLY PREGNANCY. Health Physics, 2009, 97, 82-85.	0.5	18
72	Increased serum thyroglobulin levels and negative imaging in thyroid cancer patients. Nuclear Medicine Communications, 2010, 31, 1054-1058.	1.1	17

#	Article	IF	CITATIONS
73	Variability of Hepatic 18F-FDG Uptake at Interim PET in Patients With Hodgkin Lymphoma. Clinical Nuclear Medicine, 2015, 40, e405-e410.	1.3	17
74	Performing nuclear medicine examinations in pregnant women. Physica Medica, 2017, 43, 159-164.	0.7	16
75	Improved 18-FDG PET/CT diagnosis of multiple myeloma diffuse disease by radiomics analysis. Nuclear Medicine Communications, 2021, 42, 1135-1143.	1.1	16
76	Secondary ion mass spectrometry as a tool for investigating radiopharmaceutical distribution at the cellular level: the example of I-BZA and (14)C-I-BZA. Journal of Nuclear Medicine, 2005, 46, 1701-6.	5.0	16
77	Pulmonary Metastasis of Struma Ovarii. Clinical Nuclear Medicine, 2010, 35, 692-694.	1.3	15
78	18F-Fluorocholine PET/CT as a second line nuclear imaging technique before surgery for primary hyperparathyroidism. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 654-657.	6.4	15
79	Can we avoid inadvertent parathyroidectomy during thyroid surgery?. In Vivo, 2009, 23, 433-9.	1.3	15
80	Neurotensin Receptor-1 Expression in Human Prostate Cancer: A Pilot Study on Primary Tumors and Lymph Node Metastases. International Journal of Molecular Sciences, 2019, 20, 1721.	4.1	14
81	Lenvatinib plus Pembrolizumab for Renal Cell Carcinoma. New England Journal of Medicine, 2021, 385, 287-287.	27.0	14
82	SIMS microscopy: a tool to measure the intracellular concentration of carbon 14-labelled molecules. Biology of the Cell, 1992, 74, 89-92.	2.0	13
83	Prospective comparison of 18-FDG PET/CT and whole-body diffusion-weighted MRI in the assessment of multiple myeloma. Annals of Hematology, 2020, 99, 2869-2880.	1.8	13
84	Primary Hyperparathyroidism: Defining the Appropriate Preoperative Imaging Algorithm. Journal of Nuclear Medicine, 2021, 62, 3S-12S.	5.0	13
85	Should 'low-risk' thyroid cancer patients with residual thyroglobulin be re-treated with iodine 131?. Clinical Endocrinology, 2007, 66, 329-334.	2.4	12
86	Silicon-Containing Neurotensin Analogues as Radiopharmaceuticals for NTS1-Positive Tumors Imaging. Bioconjugate Chemistry, 2020, 31, 2339-2349.	3.6	12
87	Choline PET/CT in Multiple Myeloma. Cancers, 2020, 12, 1394.	3.7	12
88	On the effectiveness of recombinant human TSH as a stimulating agent for 1311 treatment of metastatic differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 2264-2266.	6.4	11
89	Design, synthesis, and biological evaluation of a multifunctional neuropeptide-Y conjugate for selective nuclear delivery of radiolanthanides. EJNMMI Research, 2020, 10, 16.	2.5	11
90	Scintigraphic Visualization of Glossal Thyroid Tissue During the Follow-up of Thyroid Cancer Patients. Clinical Nuclear Medicine, 2007, 32, 911-914.	1.3	10

#	Article	IF	CITATIONS
91	Stimulation test in the follow-up of thyroid cancer: Plasma rhTSH levels are dependent on body weight, not endogenously stimulated TSH values. Nuclear Medicine Communications, 2007, 28, 257-259.	1.1	10
92	Association of Radioactive Iodine Treatment of Hyperthyroidism With Cancer Mortality: An Unjustified Warning?. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1901-e1902.	3.6	10
93	Prognostic and predictive value of nuclear imaging in endocrine oncology. Endocrine, 2020, 67, 9-19.	2.3	9
94	Distant metastases of differentiated thyroid cancer: diagnosis, treatment and outcome. Nuclear Medicine Review, 2007, 10, 106-9.	0.5	9
95	Parathyroid gland radionuclide scanning– methods and indications. Joint Bone Spine, 2002, 69, 28-36.	1.6	8
96	Pathological complete response in breast cancer. Lancet, The, 2015, 385, 114.	13.7	8
97	68Ga-PSMA-617 Compared With 68Ga-RM2 and 18F-FCholine PET/CT for the Initial Staging of High-Risk Prostate Cancer. Clinical Nuclear Medicine, 2019, 44, e535-e536.	1.3	8
98	Metastatic melanoma: can FDG-PET predict success of anti-PD-1 therapy and help determine when it can be discontinued?. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2227-2232.	6.4	8
99	68Ga-Radiolabeling and Pharmacological Characterization of a Kit-Based Formulation of the Gastrin-Releasing Peptide Receptor (GRP-R) Antagonist RM2 for Convenient Preparation of [68Ga]Ga-RM2. Pharmaceutics, 2021, 13, 1160.	4.5	8
100	A low thyroglobulin level cannot be used to avoid adjuvant 1311 therapy after thyroidectomy for thyroid carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 169-171.	6.4	7
101	Advanced Hodgkin's lymphoma: End-of-treatment FDG-PET should be maintained. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1254-1257.	6.4	7
102	What Is the Role of Dabrafenib Plus Trametinib Adjuvant Therapy in Stage IIIA Melanoma?. Journal of Clinical Oncology, 2019, 37, 1355-1356.	1.6	7
103	Slow Dynamic Lymphoscintigraphy Is Not a Reliable Predictor of Sentinel-Node Negativity in Cutaneous Melanoma. Cancer Biotherapy and Radiopharmaceuticals, 2008, 23, 443-450.	1.0	6
104	Nuclear Medicine in Early-Stage Melanoma: Sentinel Node Biopsy—FDG-PET/CT. PET Clinics, 2011, 6, 9-25.	3.0	6
105	Breast Cancer Patient With an Uncommon Lymphatic Drainage Evidenced by SPECT/CT. Clinical Nuclear Medicine, 2014, 39, e176-e179.	1.3	6
106	On the Role of Interim Fluorine-18–Labeled Fluorodeoxyglucose Positron Emission Tomography in Early-Stage Favorable Hodgkin Lymphoma. Journal of Clinical Oncology, 2017, 35, 2851-2852.	1.6	6
107	Risk of Hematologic Malignancies After Radioactive Iodine Treatment of Thyroid Cancer: An Unjustified Warning. Journal of Clinical Oncology, 2018, 36, 1881-1882.	1.6	6
108	Cryptorchidism as a potential source of misinterpretation in 18FDG-PET imaging in restaging lymphoma patients. Biomedicine and Pharmacotherapy, 2013, 67, 533-538.	5.6	5

#	Article	IF	CITATIONS
109	Additional Diagnostic Value of Hybrid SPECT-CT Systems Imaging in Patients With Differentiated Thyroid Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 305-313.	1.3	5
110	Radioactive iodine ablation in low-risk thyroid cancer. Lancet Diabetes and Endocrinology,the, 2018, 6, 686.	11.4	5
111	Effect of variation in relaxation parameter value on LOR-RAMLA reconstruction of 18F-FDG PET studies. Nuclear Medicine Communications, 2009, 30, 926-933.	1.1	4
112	Prospective Comparison of 18-FDG PET/CT and Whole-Body MRI with Diffusion-Weighted Imaging in the Evaluation of Treatment Response of Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplant. Cancers, 2021, 13, 1938.	3.7	4
113	Adjuvant therapy in stage IIIA melanoma. Lancet Oncology, The, 2021, 22, e299.	10.7	4
114	Accuracy of Positron Emission Tomography as a Diagnostic Tool for Lead Endocarditis: Design of the Prospective Multicentre ENDOTEP Study. European Cardiology Review, 2016, 11, 25.	2.2	4
115	Nivolumab with or without Relatlimab in Untreated Advanced Melanoma. New England Journal of Medicine, 2022, 386, 1860-1861.	27.0	4
116	La scintigraphie parathyroÃ ⁻ dienne et ses indications actuelles. Revue Du Rhumatisme (Edition) Tj ETQqO O O rgBT	lOverlock	30 Tf 50 40
117	Plasma Exchanges Overcome Persistent lodine Overload to Enable ¹³¹ I Ablation of Differentiated Thyroid Carcinoma. Thyroid, 2008, 18, 469-472.	4.5	3
118	Radiation Risk from Airport X-ray Backscatter Scanners: Should We Fear the Microsievert?. Radiology, 2011, 261, 330-331.	7.3	3
119	FDG PET/CT in Ovarian Cancer. Clinical Nuclear Medicine, 2012, 37, 54-56.	1.3	3
120	Variation de la captation hépatique de 18-FDG dans l'évaluation intermédiaire des lymphomes B diffus a grandes cellules en TEP/TDM. Medecine Nucleaire, 2014, 38, 83-90.	Ã _{0.2}	3
121	Internal Mammary Node Irradiation in Breast Cancer: The Issue of Patient Selection. Journal of Clinical Oncology, 2016, 34, 2673-2674.	1.6	3
122	Advantages and Limits of Targeted Radionuclide Therapy with Somatostatin Antagonists. Journal of Nuclear Medicine, 2018, 59, 546-547.	5.0	3
123	Prognostic utility of preâ€transplantation [18 F] fluorodeoxyglucose positron emission tomography/computed tomography in patients with diffuse large Bâ€cell lymphoma who underwent rituximab, dexamethasone, highâ€dose cytarabine, carboplatin salvage chemotherapy. British Journal of Haematology. 2020. 188. 268-271.	2.5	3
124	A Bright Future for Nuclear Endocrinology. Journal of Nuclear Medicine, 2021, 62, 1S-2S.	5.0	3
125	Parathyroid Imaging in Patients with Renal Hyperparathyroidism. , 2020, , 35-49.		3
126	Tc-99m Sestamibi and I-123 Detection of a Parathyroid Adenoma in the Presence of a Cold Thyroid Nodule. Clinical Nuclear Medicine, 1997, 22, 258-260.	1.3	3

#	Article	IF	CITATIONS
127	Prospective Comparison of 18F-Choline Positron Emission Tomography/Computed Tomography (PET/CT) and 18F-Fluorodeoxyglucose (FDG) PET/CT in the Initial Workup of Multiple Myeloma: Study Protocol of a Prospective Imaging Trial. JMIR Research Protocols, 2020, 9, e17850.	1.0	3
128	How to explain the sensitivity of DNA double-strand breaks yield to ¹²⁵ I position?. International Journal of Radiation Biology, 2023, 99, 103-108.	1.8	3
129	Backscatter xâ€ray machines at airports are safe. Medical Physics, 2012, 39, 4649-4652.	3.0	2
130	Somatostatin Antagonists for Radioligand Therapy of Nonendocrine Tumors. Journal of Nuclear Medicine, 2018, 59, 544-544.	5.0	2
131	Additional Evidence That End-of-Treatment Fluorodeoxyglucose-Positron Emission Tomography Evaluation Is Necessary in Advanced Hodgkin Lymphoma. Journal of Clinical Oncology, 2018, 36, 2124-2125.	1.6	2
132	Considerations on the Role of Pembrolizumab Adjuvant Therapy in AJCC-8 Stage IIIA Melanoma. Journal of Clinical Oncology, 2021, 39, 943-944.	1.6	2
133	Expression of neurotensin receptor-1 (NTS1) in primary breast tumors, cellular distribution, and association with clinical and biological factors. Breast Cancer Research and Treatment, 2021, 190, 403-413.	2.5	2
134	Lutetium-177–PSMA-617 for Prostate Cancer. New England Journal of Medicine, 2021, 385, 2494-2496.	27.0	2
135	Diagnostic Rechallenge with ¹⁸ Fâ€FCH PET/CT Often Allows Minimally Invasive Parathyroidectomy While Maintaining Exceptional Cure Rates. World Journal of Surgery, 2022, 46, 2409-2415.	1.6	2
136	Patient Selection for Internal Mammary Node Irradiation: Lymphoscintigraphy Can Help. Journal of Clinical Oncology, 0, , .	1.6	2
137	Monte Carlo Simulation of Electron Dose from 131I-Targeted Tumor Cells Within a Heterogeneous Tumor. Cancer Biotherapy and Radiopharmaceuticals, 2011, 26, 135-140.	1.0	1
138	Lognormal Distribution of Cellular Uptake of Radiopharmaceuticals: Implications for Biologic Response in Cancer Treatment. Journal of Nuclear Medicine, 2011, 52, 501-503.	5.0	1
139	Imaging Secondary Hyperparathyroidism. American Journal of Roentgenology, 2014, 203, W552-W552.	2.2	1
140	Re. Clinical Nuclear Medicine, 2017, 42, 576.	1.3	1
141	Interim [18F]Fluorodeoxyglucose–Positron Emission Tomography During Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer. Journal of Clinical Oncology, 2019, 37, 2091-2092.	1.6	1
142	Early use of abiraterone and radium-223 in metastatic prostate cancer. Lancet Oncology, The, 2019, 20, e229.	10.7	1
143	Diagnostic performance of imaging techniques for detecting of local recurrence after prostate brachytherapy. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2020, 24, 323-331.	1.4	1
144	Sentinel Node Biopsy in Patients With Thin Melanoma: A Need to Better Define the Aim. Journal of Clinical Oncology, 2020, 38, 3237-3238.	1.6	1

#	Article	IF	CITATIONS
145	Ribociclib plus Fulvestrant in Advanced Breast Cancer. New England Journal of Medicine, 2020, 382, e85.	27.0	1
146	18FDG-PET/CT Imaging in Breast Cancer Patients with Clinical Stage IIB or Higher. Annals of Surgical Oncology, 2020, 27, 1708-1709.	1.5	1
147	Optimising first-line treatment for metastatic renal cell carcinoma. Lancet, The, 2020, 395, e6.	13.7	1
148	Parathyroid Scintigraphy. , 2005, , .		1
149	Scintigraphie parathyroÃ⁻dienne dans l'hyperparathyroÃ⁻die primitiveÂ: quelques considérations récentes Medecine Nucleaire, 2014, 38, 208-215.	^{5.} 0.2	0
150	Putative Physiopathological Explanation for the "Sock Sign―in Bone Scans. Clinical Nuclear Medicine, 2016, 41, e420-e421.	1.3	0
151	Response to the letter by Adams and Kwee, entitled: "Unproven value of end-of-treatment FDG-PET in Hodgkin lymphoma― European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1937-1939.	6.4	0
152	Recommandations et référentiels. Medecine Nucleaire, 2019, 43, 1-4.	0.2	0
153	Thyroid cancer recurrence in the HiLo trial. Lancet Diabetes and Endocrinology,the, 2019, 7, 252.	11.4	0
154	PET-guided, BEACOPPescalated therapy in advanced Hodgkin lymphoma. Lancet Oncology, The, 2019, 20, e189.	10.7	0
155	Targeted radioactive therapy for prostate cancer. Lancet, The, 2021, 398, 487.	13.7	0
156	Predicting outcomes after 177Lu-PSMA therapy in castration-resistant prostate cancer. Lancet Oncology, The, 2021, 22, e425.	10.7	0